ALGS Stock Forecast 2025-2026
Distance to ALGS Price Targets
ALGS Price Momentum
🤔 Considering Aligos (ALGS)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest ALGS Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, ALGS has a bullish consensus with a median price target of $70.00 (ranging from $60.00 to $175.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $11.44, the median forecast implies a 511.9% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ALGS Analyst Ratings
ALGS Price Target Range
Latest ALGS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ALGS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 11, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $70.00 |
| Nov 7, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $75.00 |
| Oct 23, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $75.00 |
| Sep 20, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $75.00 |
| Aug 19, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Initiates | $75.00 |
| Jan 17, 2023 | Piper Sandler | Yasmeen Rahimi | Overweight | Maintains | $7.00 |
| Jan 6, 2023 | Jefferies | Michael Yee | Buy | Upgrade | $3.00 |
| Jan 6, 2023 | Piper Sandler | Yasmeen Rahimi | Overweight | Upgrade | $3.00 |
| Nov 3, 2022 | SVB Leerink | Roanna Ruiz | Market Perform | Maintains | $2.00 |
| May 5, 2022 | SVB Leerink | Roanna Ruiz | Market Perform | Downgrade | $3.00 |
| Mar 23, 2022 | Piper Sandler | Yasmeen Rahimi | Neutral | Downgrade | $4.00 |
| Mar 23, 2022 | SVB Leerink | Roanna Ruiz | Outperform | Maintains | $7.00 |
| Mar 11, 2022 | SVB Leerink | Roanna Ruiz | Outperform | Maintains | $11.00 |
| Mar 11, 2022 | Piper Sandler | Yasmeen Rahimi | Overweight | Maintains | $15.00 |
| Feb 16, 2022 | SVB Leerink | Roanna Ruiz | Outperform | Maintains | $10.00 |
| Jan 7, 2022 | SVB Leerink | Roanna Ruiz | Outperform | Maintains | $15.00 |
| Jan 7, 2022 | JP Morgan | Eric Joseph | Neutral | Downgrade | $12.00 |
| Sep 9, 2021 | SVB Leerink | Outperform | Initiates | $0.00 | |
| Nov 10, 2020 | Piper Sandler | Overweight | Initiates | $0.00 | |
| Nov 10, 2020 | Jefferies | Buy | Initiates | $0.00 |
Aligos Therapeutics, Inc. (ALGS) Competitors
The following stocks are similar to Aligos based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Aligos Therapeutics, Inc. (ALGS) Financial Data
Aligos Therapeutics, Inc. has a market capitalization of $69.95M with a P/E ratio of 0.0x. The company generates $3.95M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -76.5% quarter-over-quarter, while maintaining an operating margin of -3,269.2% and return on equity of -415.8%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Aligos Therapeutics, Inc. (ALGS) Business Model
About Aligos Therapeutics, Inc.
Develops therapeutics for liver diseases and infections.
Aligos Therapeutics operates by utilizing its advanced oligonucleotide and small molecule platforms to create and advance novel treatments for chronic liver diseases and viral infections. The company generates revenue through the development and potential commercialization of its drug candidates, which are aimed at addressing significant unmet medical needs in the healthcare sector.
The company's pipeline includes various drug candidates at different stages of development, focusing on innovative solutions for conditions like nonalcoholic steatohepatitis (NASH) and hepatitis B virus (HBV) infections. Aligos Therapeutics plays a significant role in the biopharmaceutical market, contributing to advancements in therapeutic approaches and aiming to expand treatment options for challenging liver conditions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
68
CEO
Dr. Lawrence M. Blatt MBA, Ph.D.
Country
United States
IPO Year
2020
Website
www.aligos.comAligos Therapeutics, Inc. (ALGS) Latest News & Analysis
Aligos Therapeutics (Nasdaq: ALGS) reported its fourth quarter and full year 2024 financial results, highlighting business progress in developing therapies for liver and viral diseases.
Aligos Therapeutics' financial results and business progress indicate its growth potential, impacting stock performance and investor confidence in the biotech sector.
Aligos Therapeutics reported a quarterly loss of $3.41 per share, worse than the expected loss of $1.91, but an improvement from a loss of $5.50 per share a year earlier.
Aligos Therapeutics' larger-than-expected quarterly loss signals potential financial instability, raising concerns about its profitability and future performance, which may impact investor confidence.
Aligos Therapeutics (Nasdaq: ALGS) will report its Q4 2024 financial results on March 10, 2025, before U.S. markets open.
Aligos Therapeutics' upcoming financial results could significantly impact its stock price, reflecting investor sentiment on its clinical progress and market potential in the biotech sector.
Aligos Therapeutics plans a private placement to raise about $105 million, funding its ALG-000184 Phase 2 study and extending its cash runway into late 2026.
Aligos Therapeutics secured $105 million for clinical studies, extending its cash runway to mid-2026, which enhances its financial stability and potential for future growth.
Aligos Therapeutics granted a new employee a non-qualified stock option to purchase 5,500 shares on December 10, 2024, as part of their employment agreement.
Aligos Therapeutics' stock option grant to a new employee signals growth and investment in talent, which can enhance future performance and innovation, potentially boosting investor confidence.
Aligos Therapeutics (Nasdaq: ALGS) reported positive data from presentations at the AASLD Liver Meeting, focused on novel therapies for liver and viral diseases.
Positive clinical data presentations can boost investor confidence and increase stock prices for Aligos Therapeutics, signaling potential advancements in its drug development pipeline.
Frequently Asked Questions About ALGS Stock
What is Aligos Therapeutics, Inc.'s (ALGS) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Aligos Therapeutics, Inc. (ALGS) has a median price target of $70.00. The highest price target is $175.00 and the lowest is $60.00.
Is ALGS stock a good investment in 2025?
According to current analyst ratings, ALGS has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $11.44. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ALGS stock?
Wall Street analysts predict ALGS stock could reach $70.00 in the next 12 months. This represents a 511.9% increase from the current price of $11.44. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Aligos Therapeutics, Inc.'s business model?
Aligos Therapeutics operates by utilizing its advanced oligonucleotide and small molecule platforms to create and advance novel treatments for chronic liver diseases and viral infections. The company generates revenue through the development and potential commercialization of its drug candidates, which are aimed at addressing significant unmet medical needs in the healthcare sector.
What is the highest forecasted price for ALGS Aligos Therapeutics, Inc.?
The highest price target for ALGS is $175.00 from at , which represents a 1,429.7% increase from the current price of $11.44.
What is the lowest forecasted price for ALGS Aligos Therapeutics, Inc.?
The lowest price target for ALGS is $60.00 from at , which represents a 424.5% increase from the current price of $11.44.
What is the overall ALGS consensus from analysts for Aligos Therapeutics, Inc.?
The overall analyst consensus for ALGS is bullish. Out of 6 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $70.00.
How accurate are ALGS stock price projections?
Stock price projections, including those for Aligos Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
